CEE= Central Easter Europe compared to US https://t.co/Zw4HPnZ8Id

• https://twitter.com/uptoTate/status/1268570425359032330

nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5

• E-CONGRESS

COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396 https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K

• E-CONGRESS

SEC shows improvement in both tender and swollen peripheral joints in AS pts. #EULAR2020 @RheumNow poster #THU0397 https://t.co/M0D6Ruh8ta https://t.co/kuShSUhXbf

• E-CONGRESS

Thoughts on the #EULAR2020 e-congress? As a life long learner, I’ve enjoyed being able to attend but I miss my interactions with colleagues @RheumNow

Interesting abstract #ABO113, out of Germany found that H. Pylori ab p66-UreB, p29-UreA, and p54-flagelin are more prominent in PsA/PsO pts. Another suggested potential link to the gut microbiome and dz? Hopefully, more data to come. #EULAR2020 @RheumNow https://t.co/mQRhsmgsHw

• EULAR Abstract Archive

This UK study to determine neutrophil function in PsA found that SEC does not affect neutrophil host defense. Check out #ABO115 for further details. An interesting find w/ regard to the inflammatory blockade and mediators of dz. #EULAR2020 @RheumNow https://t.co/EwLdlKU06A

• EULAR Abstract Archive

IL-36 as a new biomarker/tx target in SpA? Check out this interesting in vitro study out of the UK and the IL-36 upstream induction of the IL-17/IL-23 pathway. #EULAR2020 @RheumNow #SAT0356 https://t.co/YTVepexd45

• EULAR Abstract Archive

Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow

• EULAR Abstract Archive

10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3

• EULAR Abstract Archive

In regard to biosimilars, what has your experience been? #EULAR2020 @RheumNow

What do you think of #EULAR2020goesvirtual compared to an in person #EULAR? @eular_org @RheumNow @CRASCRRheum #EULAR2020goesvirtual

#EULAR2020 Friday afternoon command station with my co-worker/health and wellness coach. ⁦@KDAO2011⁩ your set up is much better! @RheumNow #bedrest https://t.co/Ldow1eemLZ

Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n

• EULAR Abstract Archive

“Let’s consider treating nr-ax SpA and axSpA as serious, similar entities for better treatment options for our patients.” Dr. D. Poddubnyy discussing EXCEED study results and extrapolation of data. #EULAR2020 @RheumNow